Antagonist of the Glucagon-like Peptide 2 (GLP-2) Receptor
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- University of Copenhagen
- Enrollment
- 10
- Locations
- 2
- Primary Endpoint
- SMA blood flow
Study Overview
Brief Summary
This project will describe the role of physiological levels of GLP-2 in regulating the blood flow to the intestines and the effect of the antagonist GLP-2(3-33) in blocking these effects of GLP-2.
Detailed Description
Ten healthy participants will meet fasting and attend four randomized experimental days of MRI-scans of the abdomen. Each day will include subcutaneous injections of GLP-2 or saline and intravenous infusion of either the GLP-2 (3-33) antagonist or saline. The infusion start at timepoint -20, while the subcutaneous injection is given to timepoint 0 and the participant will lay in the scanner in one hour after injection. Eight MR-scans are done repeatedly to measure the blood flow in larger abdominal vessels and four blood samples are taken during the experimental day for analysis of GLP-2(1-33), GLP-2(3-33) and bone markers.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Basic Science
- Masking
- Single (Participant)
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Age 18-70 years
- •BMI 19-28 kg/m2
Exclusion Criteria
- •Chronic illness that affects the cardiovascular system or gastrointestinal tract
- •Treatment with medicine or supplements that cannot be paused for 12 hours
- •Intake of above 14 alcoholic drinks per week or substance abuse
- •Liver enzymes (ALAT) above 2 times normal values
- •Decreased kidney function (eGFR below 90 or creatinine levels over reference value)
- •Low blood percentage (hemoglobin below reference value)
- •Any condition or disease that the persons responsible for the study find would interfere with the participation of the study.
Outcomes
Primary Outcomes
SMA blood flow
Time Frame: 85 minutes
Blood flow in the superior mesenteric artery
Secondary Outcomes
- PVblood flow(85 minutes)